By: IPP Bureau
Last updated : November 27, 2025 11:19 am
Renalyx will continue operating as an independent unit within the group
In a decisive push into India’s fast-evolving medical diagnostics space, recently listed Mumbai-based conglomerate Lords Mark India has snapped up an 85% stake in Bengaluru’s Renalyx Health Systems.
The holding is set to rise to 92% by March 2026. Renalyx will continue operating as an independent unit within the group.
Renalyx is the creator of the world’s first AI-powered, Made-in-India sustained low efficiency dialysis (SLED) machine — a breakthrough that aligns with India’s ambitions to become a global MedTech manufacturing powerhouse. Its flagship device, the RxT 21, is an AI- and IoT-enabled hemodialysis system capable of remote monitoring, real-time data access, clinical connectivity and support for telenephrology platforms, while boosting patient safety and care quality.
The ISO- and CE-certified system comes packed with features: integration with the DNP database for seamless center management, cloud-based EMR handling, one-touch dialysis operation, SLED mode for critical care, personalized prescriptions, Kt/V monitoring, single-needle dialysis capability, an endotoxin removal filter, and advanced sodium and ultrafiltration profiling.
Manufacturing of the dialysis machine will roll out in partnership with Bharat Electronics, following Lords Mark’s receipt of its manufacturing licence in September 2025.
Announcing the acquisition, Sachidanand Upadhyay, Managing Director & CEO of Lords Mark Industries, said, “This acquisition reinforces our commitment to driving self-reliance and innovation in India’s Medtech and Diagnostic ecosystem."
"With Renalyx Health Systems, we’re not only making advanced dialysis more accessible but also putting India on the global MedTech manufacturing map. Our goal is to scale this innovation worldwide, while ensuring that every patient, regardless of geography, has access to safe, efficient and affordable care.”
Upadhyay highlighted the company’s growing MedTech footprint, noting, “In April 2025 we shipped our first medtech order of contactless remote patient monitoring and AI based early warning systems worth $1mn to the US. This was more than just an export order for us."
"The Medtech division of the company today has innovative solutions like TuBerculoScope – an AI enabled Tuberculosis diagnostic device, Aluminium Visual Detection Kit, Extra Cellular Acidity Analyzer, Smart E Clinics, Dozee – a contactless AI enabled ICU monitoring solution besides others.”